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Abstract
Diagnosis of ongoing or past infection with Coxiella burnetii, the causative agent of Q fever, relies heavily on serology: the
measurement of C. burnetii-specific antibodies, reflecting the host’s humoral immune response. However, cell-mediated
immune responses play an important, probably even more relevant, role in infections caused by the intracellular C. burnetii
bacterium. Recent studies have investigated interferon-gamma (IFN-c) based assays, including a whole-blood IFN-c
production assay and a Coxiella enzyme-linked immunospot (Coxiella ELISPOT), as potential diagnostic tools for Q fever
diagnosis. Both are in-house developed assays using stimulating antigens of different origin. The main objective of this
study was to compare the test performance of the IFN-c production assay and the Coxiella ELISPOT for detecting a cellular
immune response to C. burnetii in Q fever patients, and to assess the correlation between both assays. To that end, both
tests were performed in a well-defined patient group of chronic Q fever patients (n = 16) and a group of healthy
seronegative individuals (n = 17). Among patients, both the Coxiella ELISPOT and the IFN-c production assay detected
positive response in 14/16. Among controls, none were positive in the Coxiella ELISPOT, whereas the IFN-c production assay
detected positive results in 1/17 and 3/17, when using Henzerling and Nine Mile as stimulating antigens, respectively. These
results suggest the Coxiella ELISPOT has a somewhat higher specificity than the IFN-c production assay when Nine Mile is
used as antigen stimulus. The assays showed moderate correlation: the Spearman correlation coefficient r ranged between
0.37–0.60, depending on the antigens used. Further investigation of the diagnostic potential for C. burnetii infection of both
assays is warranted.
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Introduction
Q fever is a zoonotic disease that occurs worldwide and is
caused by the gram-negative, intracellular bacterium Coxiella
burnetii. The Netherlands experienced a major Q fever outbreak
between 2007 and 2010, with over 4,000 reported human
infections [1]. Acute Q fever mostly presents as a flu-like illness,
pneumonia or hepatitis, but initial infections can be asymptomatic
in more than 50% of cases [2]. Chronic Q fever is a rare but
serious complication that occurs in approximately 5% of all
patients following the acute infection. This persisting infection
typically presents with endocarditis or vascular infection, and has
significant mortality rates, especially in case of diagnostic and
therapeutic delay [3].
Evaluating chronic C. burnetii infection is challenging. Mea-
surement of serum antibodies against C. burnetii is currently the
‘gold standard’ for Q fever diagnosis [3]. Diagnosis of chronic Q
fever relies heavily on detection of high IgG antibody titers against
phase 1 C. burnetii. This serological criterion is combined with
PCR for C. burnetii DNA on blood or tissue (if available) and
clinical assessment of any nidus of chronic infection [4,5].
Both humoral and cell-mediated immune responses are
involved in the host’s immunity against the intracellular C.
burnetii bacterium [6–8]. Therefore, it makes sense to explore the
value of complementing conventional serology with an assessment
of host specific cell-mediated immune responses to detect a chronic
infection with C. burnetii. To this end, new immunological blood
tests have been developed that are based on cellular immunity,
measuring T-cell derived interferon-c (IFN-c) production in
response to stimulation with C. burnetii. The first, the whole-
blood IFN-c production assay, was extensively investigated during
a Q fever vaccination campaign and for the diagnosis of chronic Q
fever [9–11]. The second, the Coxiella enzyme-linked immunospot
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(Coxiella ELISPOT), was explored in a small series of patients with
past or chronic Q fever [12]. The IFN-c production assay
measures the amount of C. burnetii specific IFN-c production,
while the Coxiella ELISPOT measures the number of C. burnetii
specific IFN-c producing cells. These IFN-c based assays are not
yet routinely used for Q fever diagnosis. Both are in-house assays,
using different stimulating antigens. The IFN-c production assay
uses in-house cultured Nine Mile phase 1 and the Q-vax vaccine
containing Henzerling phase 1, while the Coxiella ELISPOT uses
commercially available Nine Mile phase 1 and phase 2 antigens.
In the aftermath of the Dutch Q fever outbreak, we had the
opportunity to use both IFN-c based tests in parallel in a group of
well-defined chronic Q fever patients. Volunteers with no history
of Q fever and with negative Q fever serology served as a control
group.
The purpose of this study was to compare the test performance
(sensitivity and specificity) of the IFN-c production assay and the
Coxiella ELISPOT for detecting a cellular immune response to C.
burnetii in Q fever patients and to determine the correlation
between the assays.
Materials and Methods
Patients and control subjects
Chronic Q fever patients (n = 16) were recruited from the
outpatient clinics of the participating hospitals. All fulfilled the
criteria for probable (n = 4) or proven (n= 12, of which 3 Q fever
endocarditis and 9 Q fever vascular infection) chronic Q fever
according to the Dutch consensus statements on chronic Q fever
[4]. Fourteen of the 16 patients were on long-term antibiotic
treatment at inclusion. The median duration of antibiotic
treatment at the time of blood collection was 21 months (range
0–59 months). The control individuals (n = 17) were similar with
respect gender, somewhat younger, but had no history of Q fever
and had negative Q fever serology as measured by immunoflu-
orescence assay (Focus Diagnostics, Cypress, CA, USA) (Table 1).
Informed consent was obtained from all subjects before blood
donation and the study was approved by the local ethics
committee (CMO regio Arnhem-Nijmegen).
IFN-c production assay
The IFN-c production assay was performed as previously
described [9]. In short, heparinized whole blood was aliquoted
into four separate 1.5 mL tubes at 0.5 mL per tube. The tubes
were inoculated with either 10 mg/mL PHA (Sigma, St. Louis,
MO), 100 ng/ml Q vax vaccine (see below), 10‘7/mL heat-
inactivated C. burnetii Nine Mile phase I (see below), or nothing.
The tubes were incubated in-vitro for 24 hours at 37uC and 5%
CO2. The IFN-c production was measured in the supernatant by
ELISA (Pelikine compact, Sanquin, Amsterdam). Net IFN-
response was expressed as the concentration of IFN-c in the
stimulated sample minus that in the unstimulated sample.
The Q-vax vaccine (CSL Biotherapies, Vic., Australia), contains
formalin-inactivated whole cell phase 1 Henzerling strain.
Heat-inactivated phase 1 C. burnetii Nine Mile (NMI, RSA493)
was kindly provided by H.I. Roest (Central Veterinary Institute,
Lelystad, the Netherlands). Details about culture and preparation
of this stimulating antigen are described elsewhere [9].
Coxiella ELISPOT
The Coxiella ELISPOT was performed on peripheral blood
mononuclear cells (PBMCs) isolated from heparinized blood and
stimulated for 16–20 hours, as described before [12].
In precoated wells of PVDF strip plates (ELISpotpro; Mabtech)
100 mL of mononuclear cells were seeded at a density of 250,000
cells per well, and incubated with 50 mL of antigens, PHA (2.5 mg/
mL) or nothing. As stimulating antigens, commercially available
formalin-inactivated phase 1 and phase 2 Nine Mile (NMI and
NMII, Virion-Serion Immunodiagnostica GmbH, Wu¨rzburg,
Germany) were used. After incubation, the resulting number of
spots, representing the number of individual T-cells producing
IFN-c following stimulation with C. burnetii antigens, were
detected and enumerated using an ELISpot reader (Auto Immun
Diagnostika GmbH, Strassberg, Germany).
Statistics
Statistical analysis was performed using GraphPad Prism 5.
Median (6 interquartile range) IFN-c production and number of
spots were compared between groups using Mann-Whitney U-
tests. Receiver Operating Characteristics (ROC) curves analysis
were used to derive a cutoff for positivity of either assay. The cutoff
was determined from the ROC curve by choosing the value that
yielded empirical optimal sensitivity and specificity.
Correlation was reported by calculating the Spearman’s r with
95% Confidence Interval.
Results and Discussion
The amount of IFN-c as measured in the IFN-c production
assay and the spot count obtained in the Coxiella ELISPOT were
evaluated. The individual values are shown in Figure 1 for patients
and control subjects separately. The median IFN-c response to the
Henzerling antigen in the patients was 440 pg/mL (IQR 62–612
pg/mL), whereas in control subjects, this was 0 pg/mL (IQR 0–0
pg/mL). The median IFN-c response to the NMI antigen in the
patients was 3238 pg/mL (IQR 534–6564 pg/mL), whereas in
control subjects, this was 126 pg/mL (IQR 14–250 pg/mL). The
median ELISPOT spot count after NMI stimulation was 44 (IQR
Table 1. Characteristics of chronic Q fever patients and control individuals.
Patients (n =16) Controls (n =17)
Age in yrs, median (range) 68 (31–80) 46 (25–64)
Males, number (%) 13 (81) 14 (82)
IgG anti-phase I titera, median (range) 2048 (128–32768) ,16 (n.a.)
IgG anti-phase II titera, median (range) 3072 (256–32768) ,16 (n.a.)
Duration of antibiotic treatment in monthsa, median (range) 21 (0–59) n.a.
n.a., not applicable.
aAt the time of bloodsampling.
doi:10.1371/journal.pone.0103749.t001
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15–94) in patients and 0 (IQR 0–0) in controls, and after NMII
stimulation 71 (IQR 23–100) in patients and 0 (IQR 0–0) in
controls. In both assays, the differences between patients and
control subjects were significant for each stimulating antigen. All of
the samples tested responded to PHA mitogen.
To establish a cutoff for a positive response in both assays for
each of the antigens, ROC curves were constructed (Figure 2).
Cutoffs were derived from ROC curve analysis to yield empirical
optimal sensitivity and specificity. For the IFN-c production assay,
this resulted in a cutoff of 45 pg/mL or 365 pg/mL when using the
Henzerling or the NMI as stimulating antigen respectively. For the
Coxiella ELISPOT, this resulted in a cutoff of 5 spots to both NMI
and NMII. Given these cutoffs, the IFN-c production assay
detected positive response in 14/16 and the Coxiella ELISPOT
was positive in 14/16 among the patients. Among the controls, the
IFN-c production assay detected positive response in 1/17 and 3/
17, when using Henzerling and Nine Mile as stimulating antigens
respectively, whereas none were positive in the Coxiella ELI-
SPOT. These results suggest that the assays have comparable
sensitivity in this population, but the Coxiella ELISPOT has a
higher specificity than the IFN-c production assay with Nine Mile
as an antigen stimulus. This might be due to different antigens
being exposed after heat-inactivation of the NMI strain as
Figure 1. Results of the IFN-c production assay and Coxiella ELISPOT in chronic Q fever patients and control subjects. In vitro IFN-c
production by whole blood in response to Henzerling and Nine Mile phase 1 antigens was measured in the IFN-c production assay. The number of
IFN-c positive cells in response to Nine Mile phase 1 and Nine Mile phase 2 antigens was measured in the Coxiella ELISPOT. Individual values of
patients and controls are shown separately, and the lines indicate the medians. Patients and controls were compared using the Mann-Whitney U-test.
***P,0.001, **P,0.01. Abbreviations: NMI, Nine Mile phase 1; NMII, Nine Mile phase 2; IFN-c, interferon-gamma.
doi:10.1371/journal.pone.0103749.g001
Figure 2. ROC curves of the IFN-c production assay and the Coxiella ELISPOT. ROC curves are shown for each assay with each
stimulating antigen separately. Abbreviations: NMI, Nine Mile phase 1; NMII, Nine Mile phase 2; IFN-c, interferon-gamma.
doi:10.1371/journal.pone.0103749.g002
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compared to the antigens present on the formalin-inactivated
bacteria.
Furthermore, it is very well possible that the IFN-gamma
production assay and the Coxiella ELISPOT assay do not measure
the same features of the immune response. Although both tests
measure Coxiella specific IFN-gamma production, the Coxiella
ELISPOT assay singles out and quantifies the T lymphocyte
compartment, whereas whole blood stimulation also includes
blood IFN-gamma producing NK cells, reflecting also the innate
part of the immune response. However, true positives in the
control group cannot be excluded which in turn may underesti-
mate specificity. A seroprevalence study in the Q fever epidemic
area among patients with a valvular risk factor for chronic Q fever
found 20.4% of the people to be seropositive for C. burnetii [13].
As the control subjects lived close to or in the epidemic area,
although not having a Q fever history or detectable anti-C.
burnetii antibodies, it is not unthinkable that any of the control
subject could have a past exposure to C. burnetii that was not
picked up by serology. Of note, two of the three control subjects
that produced substantial amounts of IFN-c after NMI antigen
stimulation, also showed minimal response below the cutoff in the
Coxiella ELISPOT.
In the patient samples, we determined the correlation between
the amount of IFN-c produced in the IFN-c production assay and
the number of IFN-c-producing cells in the Coxiella ELISPOT
(Figure 3). The correlation between the values obtained in the two
assays, each employing two stimulating antigens, was determined
separately, resulting in a total of four comparisons. The Spearman
correlation coefficient r ranged between 0.37–0.60, indicating a
moderate to strong correlation. The discrepancies between both
types of assays can be explained by the different origins and
concentrations of stimulating antigens, the different phase
variation, or, as mentioned previously, the method of inactivation
of the antigen stimuli. Moreover, it may well be true that the
amount of IFN-c released is not directly related to the number of
IFN-c positive cells. IFN-c based assays are used for detection of
immunity to Mycobacterium tuberculosis and commercial kits are
available for the two types of assays, e.g. the QuantiFERON-TB
and the T Spot TB [14]. These assays have been reported to be at
least as accurate as the tuberculin skin test to detect exposure toM.
Figure 3. Correlation between the amount of C. burnetii-specific IFN-c production and the number of IFN-c positive cells. The
individual values of chronic Q fever patients (n = 16) were used to determine the correlation between the IFN-c production as measured with the IFN-
c production assay, and the number of IFN-c positive cells as measured with the Coxiella ELISPOT. Each graph shows the correlation between the
resulting values of the two assays, with either one of the stimulating antigens. On the Y-axes, the IFN-c production is shown after stimulation with
NMI (upper graphs) and Henzerling antigens (lower graphs). On the X-axes, the spot count is shown after stimulation with NMI (left graphs) and NMII
(right graphs) antigens. The Spearman’s correlation coefficient r (95% Confidence Interval) is given for each comparison. Abbreviations: NMI, Nine
Mile phase 1; NMII, Nine Mile phase 2; IFN-c, interferon-gamma.
doi:10.1371/journal.pone.0103749.g003
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tuberculosis. The correlation between the two types of IFN-c based
assays for tuberculosis as previously reported in the literature, are
better (r=0.69 and r=0.80) than what we observed evaluating
these diagnostic platforms in C. burnetii infection [15,16].
In conclusion, the two IFN-c based assays had a similarly high
sensitivity for detecting C. burnetii infection and the correlation
between both test was moderate. The IFN-c production assay in
whole blood has the practical advantage of relative technical
simplicity over the more laboriously intensive Coxiella ELISPOT.
The Coxiella ELISPOT, however, seemed to be more specific with
Nine Mile as an antigen stimulus. These observations, and
previous studies of these IFN-c based assays in C. burnetii
infection, show the potential of measuring cell-mediated immune
response in Q fever and warrant further investigation of these
assays in larger cohorts of Q fever patients.
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